Interviews

Alexandra S. Zimmer, MD, staff clinician, Women's Malignancies Branch, National Cancer Institute Center for Cancer Research, discusses the promising data seen thus far with olaparib (Lynparza) for the treatment of HER2-negative breast cancer.

Yelena Y. Janjigian, MD, attending physician, Memorial Sloan Kettering Cancer Center, discusses findings of CheckMate-032, a study of nivolumab (Opdivo) with or without ipilimumab (Yervoy) in patients with advanced/metastatic chemotherapy-refractory gastric, esophageal, or gastroesophageal junction cancer.

Mark Awad, MD, PhD, medical oncologist, Dana-Farber Cancer Institute, discusses the impact of MET inhibitors on survival among patients with <em>MET</em> exon 14-mutant non&ndash;small cell lung cancer.

Daniel P. Petrylak, MD,&nbsp;professor of Medicine and Urology, co-director, Signal Transduction Research Program, Yale School of Medicine, discusses the KEYNOTE-045 trial, a phase III open-label study of pembrolizumab (Keytruda) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial carcinoma.

Arjun Balar, MD, assistant professor, Department of Medicine, and director, Genitourinary Medical Oncology Program, NYU Langone Medical Center, discusses biomarker findings and mature clinical results from KEYNOTE-052, which explored first-line pembrolizumab (Keytruda) in cisplatin-ineligible advanced urothelial carcinoma.

Leena Gandhi, MD, PhD, director of the Thoracic Medical Oncology Program at NYU Langone School of Medicine, discusses first-line carboplatin and pemetrexed with or without pembrolizumab for advanced nonsquamous non&ndash;small cell lung cancer.

Sylvia Adams, MD, associate professor, Department of Medicine, NYU Langone Medical Center, discusses phase II results from cohort A of the KEYNOTE-086 trial, which explored pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer.

Alice T. Shaw, MD, PhD, director, thoracic oncology, Massachusetts General Hospital, discusses results of the phase III clinical trial comparing alectinib (Alecensa) versus crizotinib (Xalkori) in first-line treatment for ALK-positive, advanced non&ndash;small cell lung cancer.

Georgina V. Long, BSc, PhD, MBBS,&nbsp;professor of medical melanoma oncology, Melanoma Institute Australia, discusses the activity seen with the combination of dabrafenib and trametinib for the treatment of patients with melanoma brain metastases.

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, and director, Divison of Gynecologic Oncology, NYU Langone Medical Center, discusses the impact of PARP inhibitors on the landscape of ovarian cancer.

Julia Elvin, MD, PhD, vice president and senior associate medical director, Foundation Medicine, discusses a study of comprehensive genomic profiling with loss of heterozygosity to identify therapeutically relevant subsets of ovarian cancer.

Jennifer Wargo, MD, associate professor of Genomic Medicine and Surgical Oncology, discusses a study that looked at the association of the diversity and composition of the gut microbiome with responses and survival in metastatic melanoma patients on anti-PD-1 therapy.

Andrzej Jakubowiak, MD, PhD, professor of Medicine, University of Chicago Medicine, discusses safety results from an open label, phase 1b trial &nbsp;exploring daratumumab (Darzalex) combined with carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone in patients with newly diagnosed multiple myeloma.

Luis A. Diaz Jr., MD, head, Division of Solid Tumor Oncology, discusses pembrolizumab (Keytruda) therapy for microsatellite instability-high colorectal cancer and other tumor types.

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses results of the CanStem111P trial, a phase III study of napabucasin plus nab-paclitaxel with gemcitabine in adult patients with metastatic pancreatic adenocarcinoma.

Charles S. Fuchs, MD, MPH, professor of Medicine, director, Yale Cancer Center, and physician-in-chief, Smilow Cancer Hospital, discusses efficacy and safety results for pembrolizumab (Keytruda) monotherapy in patients with previously treated advanced gastric cancer.

Ragini R. Kudchadkar, MD, assistant professor, department of Hematology and Medical Oncology, Emory University School of Medicine, discusses how care for Merkel cell carcinoma has been revolutionized in recent years.&nbsp;

Sagar Lonial, MD, professor and chair, Department of Hematology &amp; Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses recent advancements in the treatment paradigm for multiple myeloma.

Phillip Abbosh, MD, PhD, assistant professor, Fox Chase Cancer Center, discusses immune correlates of pathologic response in bladder cancer patients undergoing neoadjuvant chemotherapy.

Siamak Daneshmand, MD, associate professor of Urology, Director of Clinical Research, Keck School of Medicine of USC, discusses blue light cystoscopy compared with white light cystoscopy for patients with bladder cancer.

Emma Barber, MD, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses which patients with ovarian cancer are better candidates for neoadjuvant chemotherapy versus surgery.

Joyce A. O&rsquo;Shaughnessy, MD, chair of Breast Cancer Research and the Celebrating Women Chair in Breast Cancer at Baylor-Sammons Cancer Center, discusses the promise seen with abemaciclib for the treatment of breast cancer.

Hope S. Rugo, MD, discusses the differentiating factors of abemaciclib among the CDK 4/6 inhibitors for breast cancer treatment.

Anees B. Chagpar, MD, associate professor of Surgery (Oncology), director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven, Yale Cancer Center, discusses ongoing clinical trials in the field of triple-negative breast cancer (TNBC).

Charles M. Rudin, MD, PhD, chief, thoracic oncology, Memorial Sloan Kettering Cancer, discusses a study of intravenously delivered coxsackievirus A21 with pembrolizumab to treat patients with advanced cancers.

Dhanya K. Nambiar, PhD, Stanford University, discusses a study exploring galectin-1 in combination with radiation and immune checkpoint therapy in head and neck cancers.&nbsp;

Rekha Rao, PhD, assistant professor, University of Kansas Medical Center, discusses a study of the synergistic activity of p97 inhibitors with histone deacetylase 6 inhibitors in mantle cell lymphoma (MCL).

Sophie Papa, PhD, MBBS, MRCP, King&rsquo;s College London in the United Kingdom, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with head and neck cancer.

Anna Farago, MD, PhD, assistant, medicine, Massachusetts General Hospital, discusses challenges in treating small cell lung cancer.

Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, discusses a phase 1/1b first in-human study of IPI-549, a PI3K gamma inhibitor as monotherapy and in combination with pembrolizumab (Keytruda) in patients with advanced solid tumors.